Printer Friendly

Irritable bowel syndrome in women.

January 2009

Irritable bowel syndrome (IBS) is the most common reason for gastrointestinal abdominal pain seen in primary care and gastroenterology practices, and is very prominent in gynecological practices. Up to 20% of adults in the U.S. have IBS (1), which predominantly affects reproductive-aged women, and is most likely to occur in association with, or be similar to, gynecologic disorders. In 50 percent of individuals (2), the age of onset is less than 35 years of age. (3)

IBS is a functional gastrointestinal (G1) tract disorder and is defined as chronic abdominal pain, usually lower abdomen, with disturbed bowel habits in the absence of structural or biochemical abnormalities. Bowel patterns can be diarrhea, constipation or alternating between the two. It is now suggested that abnormal gut motility and bowel hypersensitivity is influenced by psychosocial factors and the result of dysregulation of brain-gut interactions. (4), (5) Interplay between the enteric nervous system and the central autonomic neural network through parasymptathetic and sympathetic nerves regulates motor and sensory function in the intestines. This dual directional interaction between brain and gut suggests that individuals with IBS have altered perceptions of pain. (7), (8) Hyperexcitability of the neurons in the dorsal horn are thought to contribute to the prolonged pain memory in IBS patients or in a disruption in the coordination of these centers.' Communication between the brain and gut is mediated by many biochemical factors with input from the neuroendocrine and neuro immunologic body systems. Several mediators may be involved in the visceral hypersensitivity and motility including 5-hydroxylrypiamine (5-HT). 5-HT is both a neurotransmitter in bowel sensory fibers and a paracrine signaling molecule in the bowel. (12), (13) The concentration of 5-HT is considerably greater in the gut than in the brain and 95% of the body's 5-HT is synthesized and stored in the enterochromaffin cells of the gut. (14), (15)

Psychosocial factors such as early life experiences, physical stress, coping skills, psychological stressors and co-existing health problems are not thought to cause IBS, but rather influence the manifestation of symptoms and the ability to cope with the illness. Stress can affect GI function and cause various symptoms in most people, but this happens to a greater extent in IBS individuals. (16), (17), (18)

In women, there is a high prevalence of prior physical and sexual abuse in those with IBS. One study reported that 53% of gastroenterology clinic patients with functional intestinal disorders had a history of sexual abuse. (19)

Diagnosis

The characteristic description of IBS is abdominal pain or discomfort relieved by defecation. Onset is associated with a change in the consistency or frequency of the stools. A diagnostic workup includes a complete history and physical exam. Laboratory and diagnostic tests might be considered. In women < 50 y.o., these include a CBC, electrolytes, liver function tests (LFTs), occult blood and optional sigmoidoscopy. In women > 50: CBC, electrolytes, LFTs, colonoscopy or barium enema with sigmoidoscopy. Stool tests to rule out ova and parasites, bacterial or fungal overgrowth and flora imbalance can be considered as well. Diagnostic criteria are at least 12 weeks (not necessarily consecutive) in the preceding 12 months of abdominal discomfort or pain that has at least two of the following:

* relieved with defacation

* onset associated with a change in stool form/appearance

Abdominal pain or discomfort tends to be non-localized, migratory, and variable. It is often worse after a meal, during times of stress and before/during menses.

Other symptoms that increase the likely of the diagnosis of IBS but arc not essential for the diagnosis include:

* more than three stools per day or fewer than three per week

* lumpy/hard or loose/watery stools in more than 25% of the defecations

* straining, urgency, or incomplete evacuation in more than 25% of stools

* passage of mucus in more than 25% of stools

* bloating or abdominal distention more than 25% of the time

It can be helpful in treatment strategies to categorize IBS patients as constipation-predominant, diarrhea-predominant, or a combination of both at variable times. Some patients alternate between the subgroups.

Atypical symptoms should cause the practitioner to consider a diagnosis other than IBS and possibly a referral to a gastroenterologist. These include: severe constipation, persistent diarrhea, anemia, fever, weight loss, rectal bleeding, nocturnal pain, nocturnal abnormal bowel function, family history of GI cancer/ inflammatory bowel disease or celiac disease, and new onset of symptoms in those older than 50. A differential diagnosis of chronic or recurrent abdominal discomfort and bowel function includes: malabsorptive conditions (ex. Celiac), dietary factors (lactose intolerance, caffeine, sorbitol from chewing gum), infections (Giardia), inflammatory bowel disease, psychological disorders (depression), and miscellaneous conditions (ex. endometriosis, carcinoid syndrome).

Treatments

This interplay of physiological factors, psychosocial influences and trigger foods in IBS is best addressed with an integrated approach to treatment. Attending to several levels leads to the most optimal outcomes.

With high sugar/low fiber diets being so common in the U.S.. it is not surprising that an increase in dietary fiber from grain, fruits and vegetables has been a cornerstone of IBS treatment in conventional and alternative medicine approaches. Constipation dominant IBS patients appear to benefit more from using fiber/ bulking agents than do those with diarrhea. Some individuals may improve by increasing dietary fiber from fruits and vegetables and others from cereal sources although in one uncontrolled clinical study, no significant difference was observed in those who had a diet composed of 30 g of fruits and vegetable fiber and 10 g of cereal fiber vs. those with 30 g of cereal fiber with 10 g of fruit/vegetable fiber. (20) For those with a diarrhea dominant component, cooked vegetables may be the best choice to help reduce symptoms. Fiber choices in the diet and in supplement form should be individualized to sec how each patient reacts. If the fiber aggravates them, then a change to another fiber intervention, or perhaps avoiding the increased fiber approach should be considered.

There are two forms of fiber, insoluble fiber and soluble fiber. Insoluble fiber does not readily dissolve in water and increases the bulk of the stool, softens the stools and shortens the transit time. Soluble fiber dissolves in water and forms a soft gel substance and eases elimination of stool Psyllium husks and flax seeds are bulk forming agents that absorb water, soften stool and increase stool weight and the number of bowel movements per day. Even for diarrhea-dominant IBS, psyllium husks make the stools less watery. (21) However, sometimes they can increase flatulence and bloating. Citrus pectin serves as a soluble fiber in that it helps in the intestinal flora stabilization and can case both constipation and diarrhea associated IBS.(22) Guar gum is a soluble dietary fiber produced from the seed of the guar plant and is used as a bulk laxative for treating diarrhea, constipation and IBS. (23) When taken orally, it expands and normalizes bowel function. All methods of increasing fiber are best used by starting with smaller doses and slowly increasing, while also taking it with at least 8 ounces of water.

If fiber sources arc not beneficial, then osmotic laxatives such as magnesium can be utilized in those with constipation dominant IBS. Magnesium citrate, sulfate and hydroxide salts arc the most common forms of magnesium indicated for constipation. The magnesium sulfate salt is the most potent.

Most alternative medicine practitioners consider the role of food allergies or food intolerances in the etiology or course of IBS. This is based on historical empirical observation, as well as several studies documenting the association between food allergy and IBS. (24), (25), (25), (27) Identifying aggravating foods and improving the diet based on these findings along with general whole foods dietary guidelines puts the patient on a sound path towards wellness, not only with their IBS, but with their general health as well.

Recent research suggests that dysregulation in gut flora of the small bowel occurs in patients with IBS. (28) Two important clinical trials confirm this. In a randomized, placebo-controlled 5-month trial, eighty-six IBS patients were randomized to receive either a multispecies probiotic supplement daily or a placebo. (28) The IBS score at 5 months decreased 14 points from baseline with the probiotics vs. only three points with placebo. Abdominal distension and pain were especially affected. In the second clinical trial, forty IBS patients were randomized into a placebo or probiotics treatment group." After four weeks of treatment with Lactobacillus acidophilus, there was a 20% greater reduction in abdominal pain or discomfort in the treatment group vs. the placebo group.

Peppermint oil, and specifically enteric-coated peppermint oil (ECPO) inhibits gastrointestinal smooth muscle spasms of the intestinal tract and improves the rhythmic contractions, presumably due to the menthol. Peppermint oil has been studied in children (31) and adults with IBS, (32) but the results have been conflicting. A meta-analysis of five studies in 1999, was not conclusive. (33) In one of those studies, ECPO or placebo was given to 110 patients with symptoms of IBS. (34) Patients took one capsule of either 0.2ml ECPO or placebo three to four times daily 15-30 minutes before meals for one month. In all categories: abdominal pain/distension, stool frequency, gas and borborygmi, there was double to almost triple the symptom relief in the ECPO group. One problem with ECPO is that in some individuals with GERD, it can increase the symptom of heartburn. Alternative formulas without ECPO are an important clinical option.

Artichoke leaf extract, (Cynara scolymus L), has been shown to reduce the severity of IBS in a subset of patients with dyspepsia. (35) A similar study was done in patients with dyspepsia and IBS. Patients were randomly assigned to either 320 or 640 mg capsules of a standardized (1:5) aqueous extract of artichoke leaves taken daily for 2 months. (36) IBS symptoms decreased significantly by 26.4%, total symptom scores decreased by 41%, and a 20% improvement was seen in the dyspepsia index total quality-of-life score after treatment with artichoke leaf extract.

Turmeric may also help with reducing IBS symptoms. In a pilot study, 207 patients were given one tablet with 72 mg or two tablets of a standardized turmeric extract for 8 weeks. (37) IBS prevalence decreased 53% in the one tablet per day group and 60% in the two tablets per day group with approximately two thirds of all individuals reporting an improvement in symptoms after treatment.

Historically, both Western herbal medicine traditions and Traditional Chinese Medicine (TCM) has included bitters in IBS formulas. The bitters are herbs that stimulate the function and motility of the gastrointestinal (GI) tract having an effect on increasing gastric secretions and a tonic effect on the GI tract. This normalization of digestive function then is thought to balance the intestinal ecology, thereby reducing flatulence and distension. Common bitters used typically 10-30 minutes before a meal, include ginger (Zingiber officinale) rhizome, dandelion (Taraxacum officinalis), fumitory (Fumaria officianlis) leaf, wormwood (Artemisia spp.), gentian (Gentiana spp.) root, candytuft (Iberis amara) and artichoke (Cynara scolymus) leaf. From a Western botanical traditional approach, combining these bitters with herbal cholago-gues, carminatives, antispasmodics, anti-microbials, anti-inflammatories, astringents, nerviness, adaptogens, antidiarrheals and aperients (mild laxatives) can possibly address the multiplicity of IBS symptoms more effectively.

One herbal combination formula that has been studied in IBS contains the bitter candytuft (Iberis amara), a cholagogue (celandine [Chelidonium majus]) leaf and flower, carminatives (caraway [Carum carvi], peppermint [Mentha piperita], chamomile [Matricaria recutita] ): an anti-inflammatory (licorice [Glycyrrhiza spp. root] ), nervines, (lemon balm [Melissa officinalis]) angelica (Angelica archangelica), and milk thistle (silybum marianum). In a randomized, double-blind, multicenter study of 208 patients with IBS, patients received the alcohol extraction of the above herbal combination, or the above formula excluding the celandine, angelica and milk thistle, or bitter candytuft only; or placebo. (38) Twenty drops were given three times per day for four weeks. Both the full combination formula and the preparation excluding the celandine, angelica and milk thistle demonstrated effectiveness. The preparation containing the single herb, bitter candytuft did not.

Marshmallow root (Althaea officinalis) has a rich tradition for its use in constipation, diarrhea, gastric inflammation and peptic ulcers. The leaves and root contain mucilage polysaccharides that can soothe and protect mucous membranes. It is thought that this mucilaginous herb can provide a soothing effect on the intestinal wall and help stool more easily move through the bowel, thereby increasing comfort and elimination. (39)

One of my favorite herbs to use for abdominal cramping related to IBS is wild yam (Dioscorea villosa) in tincture form. The historical botanical use of wild yam includes its antispasmodic effects on smooth muscle. One teaspoon twice per day will likely yield positive results.

Two additional nutrients in supplement form are important to consider. These are tryptophan or 5-hydroxytryptophan. We mentioned in the early part of this article, the brain-gut connection. L-tryptophan and 5-hydroxytryptophan (5-HTP) are produced in both the brain and digestive tract. Approximately 95% of the body's serotonin is found in the GI tract. When the serotonin is released, it can interact with several different 5-HT (5-hydroxytryptamine) receptors. The receptor subtypes 5-[HT.sub.1], 5-[HT.sub.3] and 5-[HT.sub.4] play major roles in GI motor and secretory function as well as visceral sensation. (40) 5-[HT.sub.3] receptor antagonists delay transit in the GI tract, reduce colonic tone, dampen the gastrocolic reflex and decrease intestinal sensation. (40), (41), (42), (43) 5-[HT.sub.4] agonists improve abdominal discomfort, bloating and bowel habits in most randomized clinical trials. The critical role of 5-HT in IBS is supportive of the strategy for using alternative and conventional antidepressants because of their therapeutic ability to bind to these 5-HT receptors and affect serotonin levels. This in turn can have an influence on IBS because of its impact on the psychological factors of depression and stress. Modulation of the serotonin pathway with the use of L-tryptophan or 5-HTP, appears to be a logical approach in treating IBS. Common dosing for L-tryptophan is 500 mg up to 6,000 mg per day, before bed. Common dosing for 5-HTP is 50 mg - 100 mg/day, before bed. Be aware the tryptophan can cause side effects such as heartburn, belching, flatulence, nausea, vomiting, diarrhea, drowsiness and anorexia.

Melatonin has been studied in individuals with IBS. An eight week placebo-controlled trial demonstrated that those taking melatonin experienced 3.5 times the improvement in their IBS score. (45) In addition, quality of life was nearly 3 times greater in the melatonin group (43.6% vs. 14.6% in the placebo group). Another placebo-controlled trial of 40 individuals found that supplementing with melatonin reduced abdominal pain and rectal pain. (46) Lastly, in a study of young women with IBS, women in the melatonin group reported less abdominal pain, diarrhea and constipation after eight weeks. These IBS symptoms improved without any impact on improving sleep. (47) Typical dosing of melatonin is in the range of 0.3 mg - 5 mg nightly, before bed, although higher doses can be used.

With attention to this multifactorial, brain-gut interplay, a combination product of psyllium husk, guar gum seed extract, citrus pectin, marshmallow root, probiotics and melatonin was tested in a randomized, single-blind, two phase study in 20 volunteer subjects with IBS. Phase I of the study was done to determine the optimal dosage of melatonin. Results of the study demonstrated that nearly complete relief (over 95%) of the common symptoms of gas, bloating, constipation and diarrhea were relieved. There was also an 81.7% improvement in abdominal discomfort and 64% of the individuals had more comfortable bowel movements. (48)

Psychological/behavioral interventions are also options for IBS and can be included in a holistic approach to IBS as needed. Relaxation training, hypnosis, psychotherapy, cognitive-behavioral therapy, stress reduction and perhaps a change of pace/change in one's approach to life can be suited to each individual situation.

Conclusion

IBS is one of the most frequently diagnosed problems. It is especially common in women, and is often confused with gynecologic disorders. Although a single cause of IBS is not identified, it is generally agreed that there is interplay between physiological and psychosocial causes. Symptoms range from mild to severe. And while most patients respond to the above natural treatments, more severe cases may require selected natural therapies in conjunction with conventional antispasmodics, tricyclic antidepressants, selective serotonin reuptake inhibitors, antidiarrheals or osmotic laxatives. Alosetron, a selective [5-HT.sub.3] receptor antagonist is the first FDA-approved drug for treating severe IBS in women whose predominant symptom is diarrhea. This drug was withdrawn within months of its introduction to the market, due to serious, life-threatening gastrointestinal side effects. It was re-introduced in June 2002 with restrictions on its use.

Fortunately, IBS is very well treated with a holistic approach and attention to avoiding food triggers, increasing dietary fiber, introducing probiotics, choosing from the herbal options, and considering the interplay of the gut-brain interaction embracing melatonin/tryptophans and/or psychological/behavioral interventions.

(1) Camilleri M, Choi M. Review article: irritable bowel syndrome. Aliment Pharmacol Ther. 1997; 11:3.

(2) Everhart J, Renault P. Irritable bowel syndrome in office-based practice in the United States. Gastroenterol. 1991;I00:998.

(3) Irritable Bowel Syndrome. Mayo Clinic web site. Available at: http://www.mayoclinic.com/health/irritable-bowel-syndrome/DS00106. Accessed July 25, 2008.

(4) Ringel Y, Spcrber A, Drossman D. Irritable bowel syndrome. Ann Rev Med. 2001;52:319.

(5) Drossman D. Review article: an integrated approach to the irritable bowel syndrome. Aliment Pharmacol Ther, 1999;13(suppl):3.

(6) Goyal R, Hirano I. The enteric nervous system. NE.IM 1996;334:1 106.

(7) Wood J, Alpers D, Andrews P. Fundamentals of neurogastroenterology. Gut. 1999;45(Suppl II): 116.

(8) Drossman D. The functional gastrointestinal disorders, their diagnosis and the Rome II process. Gut. 1999; (suppl 2): III 5.

(9) Mayer E, Gebhart G. Basic and clinical aspects of visceral hyperalgesia. Gastroenterol. 1994; 107:271.

(10) Ritchie J. Pain from distention of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut. 1973:14:125.

(11) Whitehead W, Engel B, Schuster M. Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipationpredominant patients. DigDisSci. 1980;25:404.

(12) Goyal R, Hirano I. The enteric nervous system. N Engl J Med. 1996;334:1106.

(13) Bueno L, Firomonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastronenterol 1997; 112:1714.

(14) Everhart J, Renault P. Irritable bowel syndrome in office-based practice in the United Stales. Gastroenterol. 1991;100:998.

(15) Gershon M. Review article: roles played by 5hydroxytryptoamine in the physiology of the bowel. Aliment Pharmacol Ther. 1999;13(suppl 2): 15.

(16) Drossman D, Whitehead W, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterol. 1997; 1112:2120.

(17) Whitehead W, Crowell M, Robinson J, et al. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared to subjects without bowel dysfunction. Gut. 1992;33:825.

(18) Drossman D, Creed F, Fava G, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterol Int. 1995:8:47.

(19) Drossman D, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med. 1990;113:828.

(20) Fielding J, Kehoe M. Different dietary fibre formulations and the irritable bowel syndrome. Ir J Med Sci 1984:153:178-180.

(21) Marlett .J, Kajs T, Fischer M. An unfermented gel component of psyllium seed husk promotes laxation as a lubricant in humans. Am J Clin Nutr. 2000;72:784-789.

(22) Monograph. Modified citrus pectin. Altern Med Rev. 2000;5:573-575.

(23) Biaccari S, Grasso G, Tronci S, et al. Partially hydrolyzed guar gum: a fiber as coadjuvant in the irritable colon syndrome. Clin Ter 2001; 152:21 -25.

(24) Jones V, McLaughlan P, Shorthouse M, et al. Food intolerance. A major factor in the pathogenesis of irritable bowel syndrome. Lancet 1982;2:l 115-1117.

(25) Petitpierre M, Gumowski P, Girard J. Irritable bowel syndrome and hypersensitivity to food. Ann Allergy 1985;54:538-540.

(26) Nanda R, James R. Smith II, et al. Food intolerance and the irritable bowel syndrome. Gut, 1989;30:1099-1104.

(27) Gertner D, Powell-Tuck J. Irritable bowel syndrome and food intolerance. Practitioner l994;238;499-504.

(28) Riordan S, Kim R. Bacterial overgrowth as a cause of irritable bowel syndrome. Curr Opin Gastroenterol 2006;22:669-673.

(29) Kajander K, Myllyluoma E, Rajilic-Stojanovics M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008;27:48-57.

(30) Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008;53:2714 -2718.

(31) Kline R, Kline J, DiPalma J, Barbero G. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr 2001;138:125-128.

(32) Liu J, Chen G, Yeh H, Huang C, Poon S. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997;32:765-768.

(33) Pittler M, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol 1998;93:1131-1 135.

(34) Liu H, Chen G, Yeh H, et al. Enteric-coated peppermint oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997;32:765-768.

(35) Walker A, Middleton R, Petrowicz O. Artichoke leaf extract reduces symptoms of irritable bowel syndrome in a post-marketing surveillance study. Phytother Res 2001;15:58-61.

(36) Bundy R, Walker A, Middleton R. et al. Artichoke leaf extract reduces symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitant dyspepsia: A subset analysis. J Alternative and Complementary Med 2004;10(4):667-669.

(37) Bundy R, Walker A, Middleton R, Booth J. J Altern and Comp Med 2004;10(6):1015-1018.

(38) Madiseh A, Holtmann G, Pelein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: Results of a double-blind, randomized, placebo-controlled, multicentre trial. Alimentary Pharmacol Ther 2004;19:271-279.

(39) Fleming T, ed. Marshmallow. In: PDR for Herbal Medicines, Third Edition, 2004. Montvale, NJ: Medical Economics Company; 556-557.

(40) Gerson M, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132:397-414.

(41) Delvaux M, Louvel D, Mamet J, et al. Effect of alosctron on responses to colonic distention in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12:849-855.

(42) Houghton L, Forster J, Whorwell P. Alosetron, a 5[HT.sub.3] antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000;14:775-782.

(43) Mayer E, Berman S, Derbyshire S, et al. The effect of the 5-HT) receptor antagonist, alosctron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002;16:1357-1366.

(44) Ford A, Brandt L, Foxx-Orenstein A, et al. Efficacy of 5HT4-agonists in non-diarrhea predominant irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2008; 103 (suppl 1): S478 (1222).

(45) Saha L, Malhotra S, Rana S, et al. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol. 2007;41(11):29-32.

(46) Song G, Leng P, Gwee K, et al. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut. 2005;54(10):1402-7.

(47) Lu W, Gwee K. Moochhalla S, Ho K. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2005;22 (10):927-934.

(48) Massey A. Combination of fiber, probioties, and melatonin for the relief of symptoms associated with irritable bowel syndrome. Unpublished data. September 2007. Source: Technical sheet from integrative Therapeutics, Inc.

Tori Hudson, N.D.

Submitted by: Emerson Ecologics
COPYRIGHT 2009 Original Internist, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Abstracts of Interest
Author:Hudson, Tori
Publication:Original Internist
Article Type:Report
Geographic Code:1USA
Date:Jun 1, 2009
Words:3979
Previous Article:Vitamin D prevents falls.
Next Article:It really is about the DABCI community.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters